

## AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application. Support for the amendments may be found throughout the specification, including the claims as originally filed.

1. (currently amended) A composition for the targeted delivery of an therapeutic active agent to a tissue expressing asialoglycoprotein receptors comprising an effective amount of the agent encapsulated in a liposome having a molar ratio PC:Chol:PS of 11:42:0.025 coupled to desialylated glycoprotein- $\alpha$ 1.
2. (currently amended) The composition of claim 1, wherein the therapeutic agent is a drug or a polynucleotide.
3. (currently amended) The composition of claim 2, wherein the polynucleotide is cDNA encoding a therapeutic protein, a ribozyme, and antisense DNA.
4. (currently amended) The composition of claim 1, wherein the therapeutic agent is selected from the group consisting of a cytotoxic drugs, a protein.
5. (original) The composition of claim 4, wherein the cytotoxic drug is selected from the group consisting of doxorubicin, vincristine, daunorubicin, and amphiphatic amines.
6. (previously amended) The composition of claim 1, wherein the desialylated glycoprotein- $\alpha$ 1 is coupled to the liposome by an avidinbiotin or thiol-maleamide linkages.
7. (currently amended) A method for targeted delivery of a therapeutic active agent to a tissue expressing asialoglycoprotein receptors comprising delivery to the tissue an effective amount of the composition of any of claims 1 to 6.
8. Canceled

9. (currently amended) A composition for the targeted delivery of a therapeutic active agent to a tissue expressing asialoglycoproteing receptors comprising an effective amount of a doxorubicin encapsulated in a liposome having a molar ratio PC:Chol:PS of 11:0.025 coupled to desialytated glycoprotein-  $\alpha$  1 by anavidin-biotin linkage.

10. Withdrawn

## **REMARKS**

If Examiner has any questions regarding this Request for Continued Examination or the application in general, Examiner is invited to contact Applicants' attorney at the below-listed telephone number. Claims 1-7 and 9 are currently pending in this application. Claims 1-4, 7, and 9 have been amended. Support is found throughout the specification, including the claims as originally filed. No new matter has been introduced. Applicants respectfully acknowledge that a portion of the previous 35 U.S.C. §112 rejection with respect to claims 1 and 9 relating to the scope of enablement for the breadth of liposomes claimed in the present application has been overcome by the previous response dated June 5, 2003. Applicants request that the remainder of the rejection on this basis be reconsidered and withdrawn for at least the reasons stated below.

## **REJECTION UNDER U.S.C. §112, FIRST PARAGRAPH**


The Examiner states that claims 1-7 and 9 are not enabled because of the breadth of "therapeutic agents" claimed for administration for treatment purposes. The Examiner believes that the use of the language "therapeutic" in regards to the administered compounds implies a treatment effect upon administration. In order to further expedite the application toward allowance, Applicants amend the present claims deleting the term "therapeutic." The terms "active agent" is supported in the specification, for example, at paragraphs 31 and 32. For at least these reasons, Applicants respectfully request that rejection under 35 U.S.C. §112 be withdrawn.

## CONCLUSION

This communication is believed to be fully responsive to the Advisory Action and places the present application in condition for allowance. Applicants enclose a check in the amount of \$580 to accommodate the fee for the Request for Continued Examination (\$375) and the fee for a two-month extension of time (\$205) for a small entity. The Commissioner is hereby authorized to charge any deficiencies in this application to Deposit Account 13-0480, Attorney Docket Number 32144183.1336.

If a telephone interview would be of assistance in advancing prosecution of the subject application, the Examiner is requested to telephone the undersigned at the number provided below.

Respectfully submitted,



Pamela J. Wong  
Reg. No. P-54,765  
Baker & McKenzie  
2001 Ross Avenue, Suite 2300  
Dallas, TX 75201  
Ph: (619) 235-7792  
Fax: (214) 978-3099

August 6, 2003